To define whether current immune checkpoint modulators have a similar tumor eradication effect as SRC-3 KO Tregs, E0771 breast tumor–bearing SRC-3f/f female mice (C57/BL6J-Albino) were treated with an anti-PD-L1 antibody (7.5 mg/kg) or control IgG (7.5 mg/kg) twice a week for 2 wk (SI Appendix, Fig. S15A) based on a previous study (29). This evidence concerns the gene NCOA3 and neoplasm.